CLINICAL TRIALS PROFILE FOR CEFDITOREN PIVOXIL
✉ Email this page to a colleague
All Clinical Trials for Cefditoren Pivoxil
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00598403 ↗ | Efficacy and Safety of Cefditoren Pivoxil Versus Ciprofloxacin in Acute Uncomplicated Cystitis | Completed | Tedec-Meiji Farma, S.A. | Phase 3 | 2007-11-01 | The main objective of the study is to comparatively assess the efficacy and tolerability of the drugs under study in the treatment of acute uncomplicated cystitis. |
NCT01553006 ↗ | Study of Cefditoren Pivoxil in Treatment of Childhood With Acute Rhinosinusitis | Unknown status | Thammasat University | Phase 4 | 2012-01-01 | Cefditoren pivoxil has been used in rhinosinusitis treatment. However, little is known about the efficacy of this drug at low and high doses. |
NCT04709172 ↗ | Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia | Completed | Meiji Pharma Spain S.A. | Phase 4 | 2021-01-05 | The global pandemic of novel coronavirus disease 2019 (COVID-19) began in Wuhan, China, in December 2019, and has since spread worldwide. The disease is mild in 85% of cases but the remaining 15% requires hospitalization and/or intensive care. Recent publications show that a significant number of COVID-19 patients are co-infected with one or more pathogens. Most co-infections occurred within 1-4 days of onset of COVID-19 disease and a considerable number of patients arrive to the Emergency rooms with mild-moderate respiratory symptoms compatible with pneumonia of presumed bacterial origin and not severe enough for requiring hospitalization. It therefore seems reasonable to adopt therapeutic strategies for these patients that are effective and easy to follow in the outpatient setting. Cefditoren (CDN) is a third-generation cephalosporin for oral administration. CDN has a broad spectrum of activity and is particularly active against the bacterial pathogens involved in community respiratory tract infections. Besides that, the use of CDN has been associated with a marked decrease in circulating levels of IL-6 and other pro-inflammatory cytokines and mediators of epithelial damage. The aim of this study is to demonstrate that CDN improves clinical condition in patients with mild-moderate COVID-19 and symptoms of bacterial pneumonia. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Cefditoren Pivoxil
Condition Name
Clinical Trial Locations for Cefditoren Pivoxil
Clinical Trial Progress for Cefditoren Pivoxil
Clinical Trial Phase
Clinical Trial Sponsors for Cefditoren Pivoxil
Sponsor Name